Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R, Mark M. Ribi K, et al. Among authors: von briel t. BMC Cancer. 2021 Feb 19;21(1):182. doi: 10.1186/s12885-021-07903-8. BMC Cancer. 2021. PMID: 33607966 Free PMC article.
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R. Mark M, et al. Among authors: von briel t. J Bone Oncol. 2019 Dec 16;21:100273. doi: 10.1016/j.jbo.2019.100273. eCollection 2020 Apr. J Bone Oncol. 2019. PMID: 31970055 Free PMC article.
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
Stoffel ST, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MT. Stoffel ST, et al. Among authors: von briel t. Swiss Med Wkly. 2021 Mar 1;151:w20464. doi: 10.4414/smw.2021.20464. eCollection 2021 Mar 1. Swiss Med Wkly. 2021. PMID: 33705559 Free article.
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark MT, Rothschild SI, Addeo A, Janthur WD, Siano M, Boos L, Britschgi C, Früh M. Schuler A, et al. Among authors: von briel t. Lung Cancer. 2024 Jan;187:107427. doi: 10.1016/j.lungcan.2023.107427. Epub 2023 Nov 22. Lung Cancer. 2024. PMID: 38043395
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Cerny T, Leyvraz S, von Briel T, Küpfer A, Schaad R, Schmitz SF, Honegger P, Sessa C, Brunner J, Boddy AV. Cerny T, et al. Among authors: von briel t. Ann Oncol. 1999 Sep;10(9):1087-94. doi: 10.1023/a:1008386000547. Ann Oncol. 1999. PMID: 10572607 Free article. Clinical Trial.
Intradural pleural malignant mesothelioma.
Payer M, von Briel T. Payer M, et al. Among authors: von briel t. Acta Neurochir (Wien). 2007 Oct;149(10):1053-6; discussion 1056. doi: 10.1007/s00701-007-1255-5. Epub 2007 Jul 30. Acta Neurochir (Wien). 2007. PMID: 17660936 Review.